Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 15, 2025Biomarker ResearchOpen Access

Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

DKDávid KegyesABAnamaria BancosAȚAdrian Bogdan Țigu

Discussion

Loading...

Member takes

Overview

Observational analysis shows improved response rates with CELMoDs in multiple myeloma patients, suggesting potential survival benefits.

Key Points

  • CELMoDs enhance the degradation of Ikaros and Aiolos, leading to better treatment efficacy in multiple myeloma.
  • Studies indicate combined use of CELMoDs with cellular therapies yields a 10-20 times higher treatment effectiveness.
  • This review synthesizes findings from recent conferences, presenting the emerging role of targeted therapies in treating multiple myeloma.
  • Continuous evaluations show that new therapies may improve long-term outcomes, although multiple myeloma remains incurable.

Cite This Study

Kegyes et al. (2025) studied this question.

synapsesocial.com/papers/68af2b68cf1dd9ea359e4f74https://doi.org/10.1186/s40364-025-00825-8
View Full Paper
Ask AI
Bookmark
Share